CONTACT US
Home > Inhibitors/Agonists>GSK-3> > SYK Inhibitor, R406
841290-80-0-SYK Inhibitor, R406 SYK Inhibitor, R406

SYK Inhibitor, R406

For research use only. Not for therapeutic Use.

  • CAT Number: I005038
  • CAS Number: 841290-80-0
  • Molecular Formula: C₂₂H₂₃FN₆O₅
  • Molecular Weight: 470.45
  • Purity: ≥95%
Inquiry Now
Related Small Molecules: RB 6145     BPR1R024     SIC5-6    

R406（Cat No.:I005038）is a potent and selective inhibitor of spleen tyrosine kinase (SYK), a key regulator in immune cell signaling and activation. By inhibiting SYK, R406 disrupts pathways involved in inflammatory responses, making it valuable in research on autoimmune and inflammatory diseases. It has been studied for its potential in treating conditions such as rheumatoid arthritis and immune thrombocytopenia (ITP). Additionally, R406 is being explored for its anticancer properties, as SYK plays a role in certain hematologic malignancies, particularly in B-cell receptor signaling pathways.


Catalog Number I005038
CAS Number 841290-80-0
Synonyms

6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one

Molecular Formula C₂₂H₂₃FN₆O₅
Purity ≥95%
Target Spleen Tyrosine Kinase (Syk)
Solubility DMSO 20 mg/ml
Storage 3 years -20℃ powder
IC50 41 nM
IUPAC Name 6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one
InChI InChI=1S/C22H23FN6O5/c1-22(2)20(30)28-19-13(34-22)6-7-16(27-19)26-18-12(23)10-24-21(29-18)25-11-8-14(31-3)17(33-5)15(9-11)32-4/h6-10H,1-5H3,(H3,24,25,26,27,28,29,30)
InChIKey NHHQJBCNYHBUSI-UHFFFAOYSA-N
SMILES CC1(C(=O)NC2=C(O1)C=CC(=N2)NC3=NC(=NC=C3F)NC4=CC(=C(C(=C4)OC)OC)OC)C
Reference

<p style=/line-height:25px/>
<br>[1]. Braselmann S, et al. R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation. J Pharmacol Exp Ther, 2006, 319(3), 998-1008.
<br>[2]. Quiroga MP, et al. B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood, 2009, 114(5), 1029-1037.
<br>[3]. Lhermusier T, et al. The Syk-kinase inhibitor R406 impairs platelet activation and monocyte tissue factor expression triggered by heparin-PF4 complex directed antibodies. J Thromb Haemost, 2011, 9(10), 2067-2076.
<br>[4]. Zhu Y, et al. Immunotoxicity assessment for the novel Spleen tyrosine kinase inhibitor R406. Toxicol Appl Pharmacol, 2007, 221(3), 268-277.
</p>

Request a Quote